Mycophenolic acid plasma concentrations: Influence of comedication

被引:62
作者
Pou, L
Brunet, M
Cantarell, C
Vidal, E
Oppenheimer, F
Monforte, V
Vilardell, J
Roman, A
Martorell, J
Capdevila, L
机构
[1] Valle Hebron Gen Teaching Hosp, Serv Biochem, Barcelona, Spain
[2] Valle Hebron Gen Teaching Hosp, Kidney Transplant Unit, Barcelona, Spain
[3] Valle Hebron Gen Teaching Hosp, Serv Pneumol, Barcelona, Spain
[4] Univ Barcelona, Hosp Clin, Toxicol Serv, E-08007 Barcelona, Spain
[5] Univ Barcelona, Hosp Clin, Kidney Transplant Unit, E-08007 Barcelona, Spain
[6] Univ Barcelona, Hosp Clin, Serv Immunol, E-08007 Barcelona, Spain
关键词
mycophenolate mofetil; tacrolimus; cyclosporine; drug interaction; mycophenolic acid;
D O I
10.1097/00007691-200102000-00007
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Mycophenolate mofetil (MMF) in combination with cyclosporine (CsA) or Tacrolimus (TAC) has been show to be a potent immunosuppressive agent. The authors assessed the mycophenolic acid (MPA) plasma levels achieved in clinical practice and evaluated the effect of concomitant administration of CsA and TAC. One hundred forty transplant patients (kidney: 120 and lung: 20) received a triple immunosuppression regimen of CsA or TAC, prednisone and MMF. Twenty-two renal transplant patients received double therapy with MMF and prednisone. There was no correlation between MMF dose and MPA trough concentrations (r = -0.0657). The medians (range) of the MPA dose-to-concentration ratio (D/C) in the CsA and TAC groups were 0.90 (0.11-8.33) and 0.56 (0.11-14.3), respectively (p < 0.0001). According to the post transplant period (1-3, 4-6 and > 6 months), D/C values were significantly lower in patients receiving MMF and TAC than those receiving MMF and CsA in all three periods, MPA levels in patients treated with MMF and CsA were significantly lower than those obtained in double therapy. The D/C ratio in CsA-treated patients, increased significantly(p = 0.0005) when CsA level increased. There was no relationship between D/C ratio and TAC blood concentrations. These results suggest that CsA exerts an influence on MPA trough levels, although further work is required to characterize the mechanism of interaction.
引用
收藏
页码:35 / 38
页数:4
相关论文
共 20 条
[11]  
Pescovitz MD, 1998, TRANSPLANTATION, V65, P235
[12]   A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: First report [J].
Shapiro, R ;
Jordan, ML ;
Scantlebury, VP ;
Vivas, C ;
Gritsch, HA ;
Casavilla, FA ;
McCauley, J ;
Johnston, JR ;
Randhawa, P ;
Irish, W ;
Hakala, TR ;
Fung, JJ ;
Starzl, TE .
JOURNAL OF UROLOGY, 1998, 160 (06) :1982-1985
[13]   Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid [J].
Shaw, LM ;
Korecka, M ;
Van Breeman, R ;
Nowak, I ;
Brayman, KL .
CLINICAL BIOCHEMISTRY, 1998, 31 (05) :323-328
[14]   Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function [J].
Shaw, LM ;
Mick, R ;
Nowak, I ;
Korecka, M ;
Brayman, KL .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (03) :268-275
[15]  
TAKAHASHI K, 1995, TRANSPLANT P, V27, P1421
[16]   A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation [J].
van Gelder, T ;
Hilbrands, LB ;
Vanrenterghem, Y ;
Weimar, W ;
de Fijter, JW ;
Squifflet, JP ;
Hené, RJ ;
Verpooten, GA ;
Navarro, MT ;
Hale, MD ;
Nicholls, AJ .
TRANSPLANTATION, 1999, 68 (02) :261-266
[17]   Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation:: A longitudinal study in pediatric patients [J].
Weber, LT ;
Lamersdorf, T ;
Shipkova, M ;
Niedmann, PD ;
Wiesel, M ;
Zimmerhackl, LB ;
Staskewitz, A ;
Schütz, E ;
Mehls, O ;
Oellerich, M ;
Armstrong, VW ;
Tönshoff, B .
THERAPEUTIC DRUG MONITORING, 1999, 21 (05) :498-506
[18]   Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving prograf and cellcept in combination therapy [J].
Zucker, K ;
Rosen, A ;
Tsaroucha, A ;
deFaria, L ;
Roth, D ;
Ciancio, G ;
Esquenazi, V ;
Burke, G ;
Tzakis, A ;
Miller, J .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :334-336
[19]   Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation [J].
Zucker, K ;
Tsaroucha, A ;
Olson, L ;
Esquenazi, V ;
Tzakis, A ;
Miller, J .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :35-43
[20]   Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings [J].
Zucker, K ;
Rosen, A ;
Tsaroucha, A ;
deFaria, L ;
Roth, D ;
Ciancio, G ;
Esquenazi, V ;
Burke, G ;
Tzakis, A ;
Miller, J .
TRANSPLANT IMMUNOLOGY, 1997, 5 (03) :225-232